Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DOJ: Alere Unit Billed Medicare For Diabetic Testing Supplies For The Dead

Executive Summary

Alere Medical and its now-defunct subsidiary Arriva Medical will pay the US government $160m to settle allegations that they violated the False Claims Act. It’s the second settlement that Alere has entered into with the Department of Justice in recent weeks.

You may also be interested in...



2021 False Claim Judgements Top $5.6Bn; Largest Net In Seven Years

The US Department of Justice collected more than $5.6bn in settlements from civil cases involving fraud and false claims against the government in fiscal year 2021. Of that total, $1.6bn stemmed from cases brought by whistleblowers.

US DOJ Settles With St. Jude, Alere, Avanos For Total Of $88M

The settlements resolve False Claims Act allegations against St. Jude and Alere, as well as misbranding allegations against Avanos Medical.

US Joins FCA Case Against Alere Unit

Alere subsidiary Arriva Medical routinely gave Medicare beneficiaries glucometers they didn’t need and billed the government for them, a recently unsealed lawsuit claims.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel